Basilea Pharmaceutica is a leader in targeted oncology small molecules, novel antibiotics and antifungals. Since its listing in 2004 (SIX: BSLN), Basilea has launched two anti-infective treatments: Cresemba (isavuconazole) for invasive fungal infections and Zevtera (ceftobiprole), an antibiotic for severe hospital bacterial infections.

Award
  • Nominated in 2020

  • Winner in 2021